Johnson, Karen C. http://orcid.org/0000-0002-3493-4077
Pittas, Anastassios G.
Margolis, Karen L.
Peters, Anne L.
Phillips, Lawrence S.
Vickery, Ellen M.
Nelson, Jason
Sheehan, Patricia R.
Reboussin, David
Malozowski, Saul
Chatterjee, Ranee
Pittas, Anastassios G.
Brodsky, Irwin
Ceglia, Lisa
Chadha, Chhavi
Chatterjee, Ranee
Dawson-Hughes, Bess
Desouza, Cyrus
Dolor, Rowena
Foreyt, John
Ghazi, Adline
Hsia, Daniel S.
Johnson, Karen C.
Kashyap, Sangeeta R.
Kim, Sun
LeBlanc, Erin S.
Lewis, Michael R.
Liao, Emilia
Malozowski, Saul
Neff, Lisa M.
O’Neil, Patrick
Park, Jean
Peters, Anne
Phillips, Lawrence S.
Pratley, Richard
Raskin, Philip
Rasouli, Neda
Robbins, David
Rosen, Clifford
Aroda, Vanita R.
Sheehan, Patricia
Staten, Myrlene A.
Ware, James H.
Knowler, William C.
,
,
,
,
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (U34DK091958, U01DK098245)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
American Diabetes Association (1-14-D2d-01)
Article History
Received: 27 July 2021
Revised: 13 December 2021
Accepted: 5 January 2022
First Online: 9 February 2022
Change Date: 13 April 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41430-022-01130-5
Competing interests
: The following authors report no conflicts of interest Karen Johnson, Anastassios Pittas, Karen Margolis, Anne Peters, Ellen Vickery, Jason Nelson, Patricia Sheehan, David Reboussin, Saul Malozowski, Ranee Chatterjee Lawrence Phillips reports the following: Grant Support: Supported in part by VA awards CSP #2008, I01 CX001899, I01 CX001737, and HSR&D IIR 07–138, NIH awards R21 DK099716, R18 DK066204, R03 AI133172, R21 AI156161, U01 DK091958, U01 DK098246, UL1 TR002378, and a Cystic Fibrosis Foundation award PHILLI12A0. Disclosure Statement: Dr. Phillips declares that there is no duality of interest associated with this manuscript. With regard to potential conflicts of interest, Dr. Phillips has served on Scientific Advisory Boards for Boehringer Ingelheim and Janssen, and has or had research support from Merck, Pfizer, Eli Lilly, Novo Nordisk, Sanofi, PhaseBio, Roche, Abbvie, Vascular Pharmaceuticals, Janssen, Glaxo SmithKline, and the Cystic Fibrosis Foundation. Dr. Phillips is also a cofounder and Officer and Board member and stockholder of a company, Diasyst, Inc., which markets software aimed to help improve diabetes management. Anne Peters reports the following: Dr. Peters has served on scientific advisory boards for: Abbott Diabetes Care, Biorad, Eli Lilly and Company, MannKind, Medscape, Merck, Novo Nordisk, Zealand Research Support: Dexcom, vTv Therapeutics, Abbott Diabetes Care Stock Options: Omada Health, Teladoc
: A sponsor-appointed data and safety monitoring board approved the protocol and provided independent study monitoring. The institutional review board at each clinical site also approved the protocol, and all participants provided written informed consent. The study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice.